Australian Clinical Labs Limited (ASX:ACL)
Australia · Delayed Price · Currency is AUD 2.860
+0.040 (1.42%)
Aug 28, 2026, 10:23 AM AEST
Australian Clinical Labs Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 735.75 | 741.27 | 696.37 | 697.07 | 995.6 |
Other Revenue | 0.4 | - | - | - | - |
| 736.15 | 741.27 | 696.37 | 697.07 | 995.6 | |
Revenue Growth | -0.69% | 6.45% | -0.10% | -29.98% | 53.95% |
Cost of Revenue | 465.14 | 470.41 | 442.37 | 445.45 | 546.98 |
Gross Profit | 271.01 | 270.86 | 254 | 251.62 | 448.62 |
Amortization of Goodwill & Intangibles | 0.24 | 0.23 | 0.23 | 0.23 | 0.23 |
Other Operating Expenses | 66.1 | 66.81 | 63.02 | 63.65 | 68.54 |
Operating Expenses | 201.45 | 202.86 | 191.45 | 186.4 | 174.64 |
Operating Income | 69.56 | 68 | 62.55 | 65.22 | 273.98 |
Interest Expense | -14.68 | -14.59 | -12.18 | -13.47 | -11.75 |
Interest & Investment Income | 0.38 | 0.41 | 0.5 | 0.18 | 0.05 |
Other Non Operating Income (Expenses) | -3.77 | -3.78 | -4.86 | -0.4 | - |
EBT Excluding Unusual Items | 51.49 | 50.05 | 46.01 | 51.53 | 262.28 |
Merger & Restructuring Charges | -6.46 | -3.08 | -6.17 | -2.63 | -8.94 |
Legal Settlements | -6.2 | - | - | - | - |
Other Unusual Items | -1.44 | - | -4.65 | -3.28 | - |
Pretax Income | 37.39 | 48.18 | 36.37 | 48.31 | 254.9 |
Income Tax Expense | 13.38 | 15.36 | 12.12 | 12.27 | 76.5 |
Earnings From Continuing Operations | 24.02 | 32.82 | 24.24 | 36.04 | 178.4 |
Minority Interest in Earnings | -0.31 | -0.39 | -0.31 | -0.14 | -0.16 |
Net Income | 23.71 | 32.43 | 23.93 | 35.9 | 178.24 |
Net Income to Common | 23.71 | 32.43 | 23.93 | 35.9 | 178.24 |
Net Income Growth | -26.89% | 35.50% | -33.33% | -79.86% | 195.24% |
Shares Outstanding (Basic) | 192 | 199 | 199 | 201 | 201 |
Shares Outstanding (Diluted) | 192 | 200 | 199 | 201 | 201 |
Shares Change | -3.87% | 0.30% | -0.82% | -0.18% | 32.47% |
EPS (Basic) | 0.12 | 0.16 | 0.12 | 0.18 | 0.89 |
EPS (Diluted) | 0.12 | 0.16 | 0.12 | 0.18 | 0.88 |
EPS Growth | -23.94% | 35.08% | -32.77% | -79.82% | 122.88% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 153.73 | 174.39 | 153.09 | 136.75 | 262.84 |
Free Cash Flow Per Share | 0.80 | 0.87 | 0.77 | 0.68 | 1.30 |
Dividend Per Share | 0.130 | 0.125 | 0.120 | 0.140 | 0.530 |
Dividend Growth | 4.00% | 4.17% | -14.29% | -73.58% | 271.93% |
Gross Margin | 36.81% | 36.54% | 36.48% | 36.10% | 45.06% |
Operating Margin | 9.45% | 9.17% | 8.98% | 9.36% | 27.52% |
Profit Margin | 3.22% | 4.38% | 3.44% | 5.15% | 17.90% |
Free Cash Flow Margin | 20.88% | 23.53% | 21.98% | 19.62% | 26.40% |
EBITDA | 81.88 | 81.36 | 76.31 | 79.71 | 286.36 |
EBITDA Margin | 11.12% | 10.98% | 10.96% | 11.43% | 28.76% |
D&A For EBITDA | 12.32 | 13.35 | 13.76 | 14.49 | 12.37 |
EBIT | 69.56 | 68 | 62.55 | 65.22 | 273.98 |
EBIT Margin | 9.45% | 9.17% | 8.98% | 9.36% | 27.52% |
Effective Tax Rate | 35.77% | 31.88% | 33.33% | 25.39% | 30.01% |
Revenue as Reported | 736.15 | 742.49 | 697.54 | 704.76 | 997.17 |